<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="872">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00216411</nctid>
  <trial_identification>
    <studytitle>Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm</studytitle>
    <scientifictitle>A Prospective Phase IV, Multicentre, Placebo-Controlled Study to Demonstrate Changes in the Quality of Life Following DYSPORT Intramuscular Injection in the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A-9B-52120-097</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cerebrovascular Accident</healthcondition>
    <healthcondition>Muscle Spasticity</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Haemorrhagic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Botulinum type A toxin (Dysport)

Treatment: drugs: Botulinum type A toxin (Dysport)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in quality of life measured using the Assessment of Quality of Life questionnaire (12 question version).</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in muscle spasticity assessed on Modified Ashworth Scale (MAS)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in the Modified Motor Assessment Scale</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in patient disability and carer burden rating scale total score</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Achievement of the patient identified functional outcome measures (Goal Attainment Scaling)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in the degree of pain</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in depression rating scale total score</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Global assessment of benefit</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  The patient has suffered a stroke, as defined by the World Health Organisation (WHO)
             criteria, at least 6 months previously.

          -  The patient has a hemiparetic arm and meets minimum score requirements on the Modified
             Ashworth Scale.

          -  The patient has the cognitive and communication ability to participate in the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients who have received botulinum toxin treatment within the past 120 days.

          -  Contraindication to botulinum toxin treatment.

          -  Patients who are receiving oral anti-spasticity medication and who have had a change
             in dosage of this medication in the month prior to study entry.

          -  Patients who have previously been treated with phenol for their upper limb spasticity.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>St Josephs Hospital - Auburn</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Caulfield General Medical Centre - Caulfield</hospital>
    <hospital>Austin Health - Heidelberg</hospital>
    <postcode>2144 - Auburn</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3162 - Caulfield</postcode>
    <postcode>3084 - Heidelberg</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ipsen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The main purpose of this study is to assess the effect on Quality of Life of two cycles of
      Dysport treatment on post-stroke spasticity of the upper limb. The effect of treatment on
      spasticity and function will also be measured.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00216411</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Hugues Berard, MD</name>
      <address>Ipsen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>